About this trial
This study aims to obtain data on the potential influence of Vine to Bar product(s) containing Chardonnay marc on cardiometabolic health. These initial studies will inform the design and timing of data collection for future dietary intervention trials that will examine the influence of Chardonnay marc intake on outcomes/biomarkers of both cardiometabolic health and the gut microbiome. This includes collecting data on the potential differences in response to the products based on the unique food matrix for each of the products that will be tested. Moreover, as there is a paucity of data on the influence of cocoa flavanol intake on vascular function beyond 4 hours post intake, the response of the selected outcomes will be assessed after 6 hours of flavanol intake. This is a time point that captures the increased circulating presence of microbial derived flavanol metabolites.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Screening or Visit 1 Reactive Hyperemia Index (RHI; EndoPAT 2000) < 2.0
Subject is willing and able to comply with the study protocols.
Subject is willing to participate in all study procedures
BMI 25.0 - 35 kg/m2
Disqualifiers
BMI ≥ 35 kg/m2
Indivduals that weight less than a 110 lbs
Donation of blood within the previous 30 days
Visit 1 Reactive Hyperemia Index (RHI; EndoPAT 2000) ≥ 2.0
Trial design
Crossover
Treatments tested in this trial
Low Flavanol Cocoa Powder
Other interventionMeasure the response 2 and 6 hours post low flavanol cocoa intake
High Flavanol Cocoa Powder
Other interventionMeasure the response 2 and 6 hours post high flavanol cocoa intake
Vine to Bar Chocolate - 2 servings
Other interventionMeasure the response 2 and 6 hours post chocolate intake
Vine to Bar Chocolate - 1 serving
Other interventionMeasure the response 2 and 6 hours post chocolate intake
Vine to Bar Chocolate covered almonds
Other interventionMeasure the response 2 and 6 hours post chocolate covered almond intake
Treatment groups
Trial outcomes
Primary outcomes
Framingham Reactive Hyperemia Index (fRHI)
measurement of microvascular function using peripheral arterial tonometry (EndoPAT2000)
Secondary outcomes
Platelet aggregation
Platelet aggregation after collagen activation will be assessed using platelet aggregometry
soluble NADPH oxidase
measure of oxidative stress
Glucose
Plasma glucose will be measured
Insulin
Serum insulin levels will be measured
Sponsors and contacts
Click on the lead sponsor to view all of their trials.